US 11,773,126 B2
Substituted nucleosides, nucleotides and analogs thereof
Leonid Beigelman, San Mateo, CA (US); Jerome Deval, El Granada, CA (US); and Marija Prhavc, Encinitas, CA (US)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed on Aug. 26, 2021, as Appl. No. 17/446,007.
Application 17/446,007 is a continuation of application No. 16/648,405, granted, now 11,149,049, previously published as PCT/IB2018/057188, filed on Sep. 18, 2018.
Claims priority of provisional application 62/560,110, filed on Sep. 18, 2017.
Prior Publication US 2021/0395288 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 7/06 (2006.01); C07H 9/04 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01)
CPC C07H 7/06 (2013.01) [A61P 31/14 (2018.01); A61P 31/16 (2018.01); C07H 9/04 (2013.01)] 8 Claims
 
1. A compound of Formula (Ia2), having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R4A is selected from the group consisting of: fluoro, cyano, azido and C1-4alkyl substituted with one or more substituents selected from fluoro and chloro;
R5A is

OG Complex Work Unit Chemistry
R9A is

OG Complex Work Unit Chemistry
and
R33A is C1-6 alkyl.